The study population was further categorized into three groups: 92 participants (42%) had SCH with anti-TPO positivity (SCH+), 79 participants (36%) had SCH without anti-TPO positivity (SCH−), and 49 participants (22%) were euthyroid individuals, forming the control group. This evidence concerns the gene TPO and spindle cell hemangioma.